Corbus Pharmaceuticals在2025年ESCO Congress演讲之前发布了其1/2期肿瘤学研究摘要。摘要包括70名参与者的安全数据

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical stage company focused on oncology and obesity, announced today the European Society for Medical Oncology (ESMO) Congress 2025 abstract for its Phase 1/2 clinical study has been released. Updated data will be presented as a poster during ESMO. The abstract describes safety data for 70 participants from an April 2025 data cut. The poster will present updated data from a September 1st, 2025 data cut on 167 enrolled participants of which 122 participants were evaluable for efficacy with either head and neck squamous cell carcinoma (HNSCC)(n=41), cervical(n=37), metastatic urothelial tumors(n=23),or other tumor types enrolled during dose escalation(n=21).

The poster titled, "Phase 1/2 study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumours" by Perez et al, will be presented on Sunday, October 19 from 12:00-12:45 CEST (Poster # 967P).

Corbus will also host an in-person and virtual HNSCC KOL event to review and discuss the data. The event will be held at the Berlin Germany Marriott starting at 10AM CEST on Sunday October 19th. The event will feature insights from leading HNSCC experts:

• Ari Rosenberg, MD – University of Chicago
• Glenn Hanna, MD - Dana-Farber Cancer Institute
• Cesar Augusto Perez Batista, MD - Sarah Cannon Research Institute